Sareum Holdings (GB:SAR) has released an update.
Sareum Holdings has reported promising results from its Phase 1 clinical trial of SDC-1801, a TYK2/JAK1 inhibitor aimed at treating autoimmune diseases, showing significant therapeutic potential with favorable safety profiles. The company has secured substantial funding to advance SDC-1801 to Phase 2 trials and further develop its cancer immunotherapy candidate, SDC-1802. With strengthened intellectual property and a robust financial position, Sareum is poised for significant strides in its drug development programs.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
